Table 5. Multivariate Cox regression analysis of PFS of 55 patients.
| Characteristics | HR | 95% CI | P |
|---|---|---|---|
| Cycles of regorafenib plus PD-1 | <0.001 | ||
| 1 | Reference | ||
| >1 | 0.12 | (0.05, 0.31) | |
| Treatment | 0.044 | ||
| The other PD-1 | Reference | ||
| Sintilimab | 0.55 | (0.31, 0.99) | |
| Sex | 0.77 | ||
| Male | Reference | ||
| Female | 0.91 | (0.51, 1.65) | |
| Radiotherapy | 0.86 | ||
| No | Reference | ||
| Yes | 0.94 | (0.49, 1.81) | |
| Previous lines of chemotherapy | 0.99 | ||
| ≥3 lines | Reference | ||
| 2 line | 1 | (0.56, 1.76) | |
PFS, progression-free survival; PD-1, programmed cell death protein 1; HR, hazard ratio; CI, confidence interval.